While Goldman Sachs maintains a 'Buy' rating on Calumet Specialty Prods, the lowering of the price target from $19 to $17 could potentially create some uncertainty among investors. However, the 'Buy' rating suggests that the firm still sees potential in the stock, which could balance out any negative sentiment.